Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Rasa S, Nora-Krukle Z, Henning N, Eliassen E, Shikova E, Harrer T, Scheibenbogen C, Murovska M, Prusty BK; European Network on ME/CFS (EUROMENE).

J Transl Med. 2018 Oct 1;16(1):268. doi: 10.1186/s12967-018-1644-y. Review.

2.

Long-term follow-up of HIV-1-infected adults who received the F4/AS01B HIV-1 vaccine candidate in two randomised controlled trials.

Harrer T, Dinges W, Roman F; TH-HIV-011 study group.

Vaccine. 2018 May 3;36(19):2683-2686. doi: 10.1016/j.vaccine.2018.03.043. Epub 2018 Mar 30.

3.

Head and Neck Kaposi Sarcoma: Clinicopathological Analysis of 11 Cases.

Agaimy A, Mueller SK, Harrer T, Bauer S, Thompson LDR.

Head Neck Pathol. 2018 Dec;12(4):511-516. doi: 10.1007/s12105-018-0902-x. Epub 2018 Mar 5.

4.

Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation.

Hecht M, Harrer T, Körber V, Sarpong EO, Moser F, Fiebig N, Schwegler M, Stürzl M, Fietkau R, Distel LV.

Oncol Lett. 2018 Feb;15(2):1728-1736. doi: 10.3892/ol.2017.7523. Epub 2017 Dec 5.

5.

HIV Activates the Tyrosine Kinase Hck to Secrete ADAM Protease-Containing Extracellular Vesicles.

Lee JH, Ostalecki C, Zhao Z, Kesti T, Bruns H, Simon B, Harrer T, Saksela K, Baur AS.

EBioMedicine. 2018 Feb;28:151-161. doi: 10.1016/j.ebiom.2018.01.004. Epub 2018 Jan 4. No abstract available.

6.

Life-Threatening Atypical Case of Acute Generalized Exanthematous Pustulosis.

Tajmir-Riahi A, Wörl P, Harrer T, Schliep S, Schuler G, Simon M.

Int Arch Allergy Immunol. 2017;174(2):108-111. doi: 10.1159/000480700. Epub 2017 Oct 25.

PMID:
29065395
7.

Experimental lupus is aggravated in mouse strains with impaired induction of neutrophil extracellular traps.

Kienhöfer D, Hahn J, Stoof J, Csepregi JZ, Reinwald C, Urbonaviciute V, Johnsson C, Maueröder C, Podolska MJ, Biermann MH, Leppkes M, Harrer T, Hultqvist M, Olofsson P, Munoz LE, Mocsai A, Herrmann M, Schett G, Holmdahl R, Hoffmann MH.

JCI Insight. 2017 May 18;2(10). pii: 92920. doi: 10.1172/jci.insight.92920. eCollection 2017 May 18.

8.

HIV Nef- and Notch1-dependent Endocytosis of ADAM17 Induces Vesicular TNF Secretion in Chronic HIV Infection.

Ostalecki C, Wittki S, Lee JH, Geist MM, Tibroni N, Harrer T, Schuler G, Fackler OT, Baur AS.

EBioMedicine. 2016 Nov;13:294-304. doi: 10.1016/j.ebiom.2016.10.027. Epub 2016 Oct 19.

9.

Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.

Borte M, Kriván G, Derfalvi B, Maródi L, Harrer T, Jolles S, Bourgeois C, Engl W, Leibl H, McCoy B, Gelmont D, Yel L.

Clin Exp Immunol. 2017 Jan;187(1):146-159. doi: 10.1111/cei.12866. Epub 2016 Oct 18.

10.

Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.

Lankes K, Hundorfean G, Harrer T, Pommer AJ, Agaimy A, Angelovska I, Tajmir-Riahi A, Göhl J, Schuler G, Neurath MF, Hohenberger W, Heinzerling L.

Oncoimmunology. 2016 Feb 18;5(6):e1128611. doi: 10.1080/2162402X.2015.1128611. eCollection 2016 Jun.

11.

T-cell receptor transfer for boosting HIV-1-specific T-cell immunity in HIV-1-infected patients.

Mummert C, Hofmann C, Hückelhoven AG, Bergmann S, Mueller-Schmucker SM, Harrer EG, Dörrie J, Schaft N, Harrer T.

AIDS. 2016 Sep 10;30(14):2149-58. doi: 10.1097/QAD.0000000000001176.

PMID:
27258398
12.

HIV-Nef and ADAM17-Containing Plasma Extracellular Vesicles Induce and Correlate with Immune Pathogenesis in Chronic HIV Infection.

Lee JH, Schierer S, Blume K, Dindorf J, Wittki S, Xiang W, Ostalecki C, Koliha N, Wild S, Schuler G, Fackler OT, Saksela K, Harrer T, Baur AS.

EBioMedicine. 2016 Apr;6:103-113. doi: 10.1016/j.ebiom.2016.03.004. Epub 2016 Mar 3.

13.

Improved tag-switch method reveals that thioredoxin acts as depersulfidase and controls the intracellular levels of protein persulfidation.

Wedmann R, Onderka C, Wei S, Szijártó IA, Miljkovic JL, Mitrovic A, Lange M, Savitsky S, Yadav PK, Torregrossa R, Harrer EG, Harrer T, Ishii I, Gollasch M, Wood ME, Galardon E, Xian M, Whiteman M, Banerjee R, Filipovic MR.

Chem Sci. 2016 May 25;7(5):3414-3426. Epub 2016 Feb 19.

14.

PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis.

Fätkenheuer G, Jessen H, Stoehr A, Jung N, Jessen AB, Kümmerle T, Berger M, Bogner JR, Spinner CD, Stephan C, Degen O, Vogelmann R, Spornraft-Ragaller P, Schnaitmann E, Jensen B, Ulmer A, Kittner JM, Härter G, Malfertheiner P, Rockstroh J, Knecht G, Scholten S, Harrer T, Kern WV, Salzberger B, Schürmann D, Ranneberg B.

HIV Med. 2016 Jun;17(6):453-9. doi: 10.1111/hiv.12363. Epub 2016 May 11.

15.

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.

Dinges W, Girard PM, Podzamczer D, Brockmeyer NH, García F, Harrer T, Lelievre JD, Frank I, Colin De Verdière N, Yeni GP, Ortega Gonzalez E, Rubio R, Clotet Sala B, DeJesus E, Pérez-Elias MJ, Launay O, Pialoux G, Slim J, Weiss L, Bouchaud O, Felizarta F, Meurer A, Raffi F, Esser S, Katlama C, Koletar SL, Mounzer K, Swindells S, Baxter JD, Schneider S, Chas J, Molina JM, Koutsoukos M, Collard A, Bourguignon P, Roman F.

Medicine (Baltimore). 2016 Feb;95(6):e2673. doi: 10.1097/MD.0000000000002673.

16.

A Multiplex Kindred with Hennekam Syndrome due to Homozygosity for a CCBE1 Mutation that does not Prevent Protein Expression.

Jackson CC, Best L, Lorenzo L, Casanova JL, Wacker J, Bertz S, Agaimy A, Harrer T.

J Clin Immunol. 2016 Jan;36(1):19-27. doi: 10.1007/s10875-015-0225-6. Epub 2015 Dec 19.

17.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

18.

Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells.

Hecht M, Erber S, Harrer T, Klinker H, Roth T, Parsch H, Fiebig N, Fietkau R, Distel LV.

PLoS One. 2015 Jun 18;10(6):e0130277. doi: 10.1371/journal.pone.0130277. eCollection 2015.

19.

Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab.

Uslu U, Agaimy A, Hundorfean G, Harrer T, Schuler G, Heinzerling L.

J Immunother. 2015 Jun;38(5):212-5. doi: 10.1097/CJI.0000000000000081.

PMID:
25962110
20.

Cross-Reactivity Between Influenza Matrix- and HIV-1 P17-Specific CTL-A Large Cohort Study.

Hückelhoven AG, Etschel JK, Bergmann S, Zitzelsberger K, Mueller-Schmucker SM, Harrer EG, Harrer T.

J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):528-35. doi: 10.1097/QAI.0000000000000657.

PMID:
25900164
21.

Identification of HLA-C restricted, HIV-1-specific CTL epitopes by peptide induced upregulation of HLA-C expression.

Stoll A, Bergmann S, Mummert C, Mueller-Schmucker SM, Spriewald BM, Harrer EG, Harrer T.

J Immunol Methods. 2015 Mar;418:9-18. doi: 10.1016/j.jim.2015.01.005. Epub 2015 Jan 26.

PMID:
25633660
22.

The progression of cell death affects the rejection of allogeneic tumors in immune-competent mice - implications for cancer therapy.

Chaurio RA, Muñoz LE, Maueröder C, Janko C, Harrer T, Fürnrohr BG, Niederweis M, Bilyy R, Schett G, Herrmann M, Berens C.

Front Immunol. 2014 Nov 11;5:560. doi: 10.3389/fimmu.2014.00560. eCollection 2014.

23.

Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines.

Schauer C, Janko C, Munoz LE, Zhao Y, Kienhöfer D, Frey B, Lell M, Manger B, Rech J, Naschberger E, Holmdahl R, Krenn V, Harrer T, Jeremic I, Bilyy R, Schett G, Hoffmann M, Herrmann M.

Nat Med. 2014 May;20(5):511-7. doi: 10.1038/nm.3547. Epub 2014 Apr 28.

PMID:
24784231
24.

Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.

Harrer T, Plettenberg A, Arastéh K, Van Lunzen J, Fätkenheuer G, Jaeger H, Janssens M, Burny W, Collard A, Roman F, Loeliger A, Koutsoukos M, Bourguignon P, Lavreys L, Voss G.

Vaccine. 2014 May 7;32(22):2657-65. doi: 10.1016/j.vaccine.2013.10.030. Epub 2013 Oct 19.

25.

Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system.

Hecht M, Harrer T, Büttner M, Schwegler M, Erber S, Fietkau R, Distel LV.

AIDS. 2013 Aug 24;27(13):2031-40. doi: 10.1097/QAD.0b013e3283625444.

PMID:
23612009
26.

HIV Nef, paxillin, and Pak1/2 regulate activation and secretion of TACE/ADAM10 proteases.

Lee JH, Wittki S, Bräu T, Dreyer FS, Krätzel K, Dindorf J, Johnston IC, Gross S, Kremmer E, Zeidler R, Schlötzer-Schrehardt U, Lichtenheld M, Saksela K, Harrer T, Schuler G, Federico M, Baur AS.

Mol Cell. 2013 Feb 21;49(4):668-79. doi: 10.1016/j.molcel.2012.12.004. Epub 2013 Jan 11.

27.

Elevated CD40 ligand silences α interferon production in an HIV-related immune reconstitution inflammatory syndrome.

Tennert K, Schneider L, Bischof G, Korn K, Harrer E, Harrer T, Schmidt B; German Competence Network HIVAIDS.

AIDS. 2013 Jan 14;27(2):297-9. doi: 10.1097/QAD.0b013e328359f2f9. No abstract available.

PMID:
23238554
28.

HIV-1 mRNA electroporation of PBMC: a simple and efficient method to monitor T-cell responses against autologous HIV-1 in HIV-1-infected patients.

Etschel JK, Hückelhoven AG, Hofmann C, Zitzelsberger K, Maurer K, Bergmann S, Mueller-Schmucker SM, Wittmann J, Spriewald BM, Dörrie J, Schaft N, Harrer T.

J Immunol Methods. 2012 Jun 29;380(1-2):40-55. doi: 10.1016/j.jim.2012.03.005. Epub 2012 Apr 3.

PMID:
22510580
29.

HIV-associated hypertrophic herpes simplex genitalis with concomitant early invasive squamous cell carcinoma mimicking advanced genital cancer: case report and literature review.

Strehl JD, Mehlhorn G, Koch MC, Harrer EG, Harrer T, Beckmann MW, Agaimy A.

Int J Gynecol Pathol. 2012 May;31(3):286-93. doi: 10.1097/PGP.0b013e318237d581. Review.

PMID:
22498948
30.

Chronic immune activation in HIV-1 infection contributes to reduced interferon alpha production via enhanced CD40:CD40 ligand interaction.

Donhauser N, Pritschet K, Helm M, Harrer T, Schuster P, Ries M, Bischof G, Vollmer J, Smola S, Schmidt B; German Competence Network HIV/AIDS.

PLoS One. 2012;7(3):e33925. doi: 10.1371/journal.pone.0033925. Epub 2012 Mar 21.

31.

Renal leishmaniasis as unusual cause of nephrotic syndrome in an HIV patient.

Amann K, Bogdan C, Harrer T, Rech J.

J Am Soc Nephrol. 2012 Apr;23(4):586-90. doi: 10.1681/ASN.2011050472. Epub 2012 Jan 26.

32.

Human T cells expressing two additional receptors (TETARs) specific for HIV-1 recognize both epitopes.

Hofmann C, Höfflin S, Hückelhoven A, Bergmann S, Harrer E, Schuler G, Dörrie J, Schaft N, Harrer T.

Blood. 2011 Nov 10;118(19):5174-7. doi: 10.1182/blood-2011-04-347005. Epub 2011 Sep 16.

33.

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS Coordinators.

J Antimicrob Chemother. 2011 Sep;66(9):2092-8. doi: 10.1093/jac/dkr272. Epub 2011 Jun 29.

34.

The immune response to the RT181-189 epitope in HIV-1-infected patients is associated with viral sequence polymorphism flanking the epitope.

Pacheco Y, Allavena C, Guilloux Y, Mueller-Schmucker SM, Hueckelhoven AG, André-Garnier E, Cleon F, Ferré V, Rodallec A, Billaud E, Harrer T, Raffi F, McIlroy D.

J Clin Immunol. 2011 Aug;31(4):681-9. doi: 10.1007/s10875-011-9520-z. Epub 2011 Apr 14.

PMID:
21491096
35.

[Bilateral vision loss in a patient with weight loss and neurologic symptoms].

La Mancusa A, Rech J, Harrer T, Knorr H, Bergua A.

Klin Monbl Augenheilkd. 2011 Jul;228(7):639-40. doi: 10.1055/s-0029-1245751. Epub 2011 Mar 30. German. No abstract available.

PMID:
21452106
36.

Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognition.

Mueller SM, Spriewald BM, Bergmann S, Eismann K, Leykauf M, Korn K, Walter H, Schmidt B, Arnold ML, Harrer EG, Kaiser R, Schweitzer F, Braun P, Reuter S, Jaeger H, Wolf E, Brockmeyer NH, Jansen K, Michalik C, Harrer T; German Competence Network for HIV/AIDS.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):109-17. doi: 10.1097/QAI.0b013e3181fe946e.

PMID:
21107269
37.

Analysis of immune selection as a potential cause for the presence of cleavage site mutation 431V in treatment-naive HIV type-1 isolates.

Verheyen J, Schweitzer F, Harrer EG, Knops E, Mueller SM, Däumer M, Eismann K, Bergmann S, Spriewald BM, Kaiser R, Harrer T.

Antivir Ther. 2010;15(6):907-12. doi: 10.3851/IMP1640.

PMID:
20834103
38.

A typically atypical tenosynovitis.

Sahinbegovic E, Arco G, Cavallaro A, Söder S, Schörner C, Schett G, Harrer T, Zwerina J.

Clin Rheumatol. 2013 Mar;32 Suppl 1:S87-8. doi: 10.1007/s10067-010-1518-z. Epub 2010 Jun 27.

PMID:
20582608
39.

Oropharyngeal tularemia--a differential diagnosis of tonsillopharyngitis and cervical lymphadenitis.

Dlugaiczyk J, Harrer T, Zwerina J, Traxdorf M, Schwarz S, Splettstoesser W, Geissdörfer W, Schoerner C.

Wien Klin Wochenschr. 2010 Feb;122(3-4):110-4. doi: 10.1007/s00508-009-1274-8.

PMID:
20213378
40.

HIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008.

Stellbrink HJ, Baldus S, Behrens G, Bogner JR, Harrer T, Hoffmann C, van Lunzen J, Münch J, Racz P, Scheller C, Stoll M, Tenner-Racz K, Rockstroh J.

Eur J Med Res. 2010 Jan 29;15(1):1-12.

41.

Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir.

Beck-Engeser GB, Eilat D, Harrer T, Jäck HM, Wabl M.

Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20865-70. doi: 10.1073/pnas.0908074106. Epub 2009 Nov 18.

42.

Epidemiological composition, clinical and treatment characteristics of the patient cohort of the German Competence Network for HIV/AIDS.

Jansen K, Brockmeyer NH, Hahn M, Kaul I, Fenske S, Rausch M, Kuhlmann B, Ulmer A, Lauenroth-Mai E, Harrer T, Hower M, Skaletz-Rorowski A, Michalik C; Competence Network for HIV/AIDS.

Eur J Med Res. 2009 Sep 28;14(10):415-25.

43.

A fast and robust method to clone and functionally validate T-cell receptors.

Birkholz K, Hofmann C, Hoyer S, Schulz B, Harrer T, Kämpgen E, Schuler G, Dörrie J, Schaft N.

J Immunol Methods. 2009 Jul 31;346(1-2):45-54. doi: 10.1016/j.jim.2009.05.001. Epub 2009 May 7.

PMID:
19427315
44.

O-linked N-acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter.

Jochmann R, Thurau M, Jung S, Hofmann C, Naschberger E, Kremmer E, Harrer T, Miller M, Schaft N, Stürzl M.

J Virol. 2009 Apr;83(8):3704-18. doi: 10.1128/JVI.01384-08. Epub 2009 Feb 4.

45.

Generation of HIV-1-specific T cells by electroporation of T-cell receptor RNA.

Hofmann C, Harrer T, Kubesch V, Maurer K, Metzner KJ, Eismann K, Bergmann S, Schmitt-Haendle M, Schuler G, Dörrie J, Schaft N.

AIDS. 2008 Aug 20;22(13):1577-82. doi: 10.1097/QAD.0b013e3283063a17.

PMID:
18670216
46.

Bypassing non-adherence via PEG in a critically ill HIV-1-infected patient.

Leipe J, Hueber AJ, Rech J, Harrer T.

AIDS Care. 2008 Aug;20(7):863-7. doi: 10.1080/09540120701767182.

PMID:
18608059
47.

Role of cytotoxic T-lymphocyte-mediated immune selection in a dominant human leukocyte antigen-B8-restricted cytotoxic T-lymphocyte epitope in Nef.

Maurer K, Harrer EG, Goldwich A, Eismann K, Bergmann S, Schmitt-Haendle M, Spriewald B, Mueller SM, Harrer T; German Competence Network for HIV/AIDS.

J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):133-41. doi: 10.1097/QAI.0b013e31816fdc4a. Erratum in: J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):343.

PMID:
18391752
48.

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, Fätkenheuer G, Khoo SH, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS.

J Antimicrob Chemother. 2008 Apr;61(4):914-8. doi: 10.1093/jac/dkn029. Epub 2008 Feb 14.

49.

Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and its homologue DC-SIGNR.

Marzi A, Möller P, Hanna SL, Harrer T, Eisemann J, Steinkasserer A, Becker S, Baribaud F, Pöhlmann S.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S237-46.

PMID:
17940955
50.

Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication.

Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, Rinaldo CR, Craggs SL, Allgaier RL, Power KA, Kuntzen T, Tung CS, LaBute MX, Mueller SM, Harrer T, McMichael AJ, Goulder PJ, Aiken C, Brander C, Kelleher AD, Allen TM.

J Virol. 2007 Nov;81(22):12382-93. Epub 2007 Sep 5.

Supplemental Content

Loading ...
Support Center